These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 27888901)
1. [Monoclonal antibodies against PCSK9: from bench to clinic]. Guijarro Herraiz C Clin Investig Arterioscler; 2016 May; 28 Suppl 2():14-21. PubMed ID: 27888901 [TBL] [Abstract][Full Text] [Related]
2. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. Lambert G; Thedrez A; Croyal M; Ramin-Mangata S; Couret D; Diotel N; Nobécourt-Dupuy E; Krempf M; LeBail JC; Poirier B; Blankenstein J; Villard EF; Guillot E Clin Sci (Lond); 2017 Feb; 131(4):261-268. PubMed ID: 28108631 [TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748 [TBL] [Abstract][Full Text] [Related]
4. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417 [TBL] [Abstract][Full Text] [Related]
5. [Anti-PCSK9 antibodies in type 2 diabetes and secondary prevention of cardiovascular diseases]. López-Miranda J; Pintó X Clin Investig Arterioscler; 2016 May; 28 Suppl 2():31-38. PubMed ID: 27888904 [TBL] [Abstract][Full Text] [Related]
6. Status of PCSK9 Monoclonal Antibodies in Australia. Scherer DJ; Nelson AJ; O'Brien R; Kostner KM; Hare DL; Colquhoun DM; Barter PJ; Aylward P; Nicholls SJ; Watts GF Heart Lung Circ; 2019 Oct; 28(10):1571-1579. PubMed ID: 31104887 [TBL] [Abstract][Full Text] [Related]
7. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Catapano AL; Papadopoulos N Atherosclerosis; 2013 May; 228(1):18-28. PubMed ID: 23466067 [TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Blom DJ; Dent R; Castro RC; Toth PP Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264 [TBL] [Abstract][Full Text] [Related]
9. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. Schiele F; Park J; Redemann N; Luippold G; Nar H J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255 [TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Elbitar S; Khoury PE; Ghaleb Y; Rabès JP; Varret M; Seidah NG; Boileau C; Abifadel M Expert Opin Ther Pat; 2016 Dec; 26(12):1377-1392. PubMed ID: 27359211 [TBL] [Abstract][Full Text] [Related]
11. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Tavori H; Melone M; Rashid S Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623 [TBL] [Abstract][Full Text] [Related]
12. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation. Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794 [TBL] [Abstract][Full Text] [Related]
13. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873 [TBL] [Abstract][Full Text] [Related]
14. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Banerjee Y; Santos RD; Al-Rasadi K; Rizzo M Atherosclerosis; 2016 May; 248():62-75. PubMed ID: 26987067 [TBL] [Abstract][Full Text] [Related]
16. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
17. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Roth EM; Diller P Future Cardiol; 2014 Mar; 10(2):183-99. PubMed ID: 24762246 [TBL] [Abstract][Full Text] [Related]
18. PCSK9: a key modulator of cardiovascular health. Seidah NG; Awan Z; Chrétien M; Mbikay M Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727 [TBL] [Abstract][Full Text] [Related]
19. Use and role of monoclonal antibodies and other biologics in preventive cardiology. Gencer B; Laaksonen R; Buhayer A; Mach F Swiss Med Wkly; 2015; 145():w14179. PubMed ID: 26524671 [TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]